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The development of local anesthesia in dentistry has marked the beginning of a new era in terms of pain control. Lignocaine
is the most commonly used local anesthetic (LA) agent even though it has a vasodilative eﬀect and needs to be combined with
adrenaline. Centbucridine is a non-ester, non amide group LA and has not been comprehensively studied in the dental setting
and the objective was to compare it to Lignocaine. This was a randomized study comparing the onset time, duration, depth and
cardiovascular parameters between Centbucridine (0.5%) and Lignocaine (2%). The study was conducted in the dental outpatient
department at the Government Dental College in India on patients attending for the extraction of lower molars. A total of 198
patientswereincludedandtherewerenosigniﬁcantdiﬀerencesbetweentheLAsexceptthosewhoreceivedCentbucridinereported
a signiﬁcantly longer duration of anesthesia compared to those who received Lignocaine. None of the patients reported any side
eﬀects. Centbucridine was well tolerated and its substantial duration of anesthesia could be attributed to its chemical compound.
Centbucridine can be used for dental procedures and can conﬁdently be used in patients who cannot tolerate Lignocaine or where
adrenaline is contraindicated.
1.Introduction
The ability to provide the patient with clinically adequate
pain control is one of the major concerns all over the
world. The development of local anesthesia has marked the
beginning of new era in the ﬁeld of dentistry. The use of local
anesthetics (LAs) in dentistry and other surgical procedures
as a means of pain control has been one of the medical
marvels of twentieth century [1, 2]. Today Lignocaine is the
most commonly used local anesthetic agent in dentistry and
is referred to as the “gold standard” for dental procedures
[1, 2]. Although its properties resemble an ideal LA agent, it
is not completely free from cardiovascular toxicity and has
an inherent vasodilating property [1, 3, 4]. As a result of
the vasodilating characteristic, it has to be combined with
a vasoconstrictor, such as adrenaline, to decrease its rate of
absorption at the injection site and hence prolong the dura-
tion and depth of anesthesia. The use of adrenaline as a vaso-
constrictor is sometimes contraindicated for medically com-
promised patients. To overcome these disadvantages, other
LAs have been developed over the past few years, including
Centbucridine.
Centbucridine, chemically known as 4-N-butylamino-
1,2,3,4-tetrahydroacridine hydrochloride, is a new quinoline
derivative with LA action. It was synthesized at the central
drug research institute, Lucknow, India, by Patnaik et al.
and has the advantage of having an inherent vasoconstrictor
property [4].
Many studies have been done on Centbucridine in the
medical ﬁeld including ophthalmic surgery [5, 6], subarach-
noid [7], and spinal [8] blocks. However, in dentistry, only
a few have been published [2, 9, 10], and most of them
were carried out in the early eighties. However, all of the
published literature has shown Centbucridine as a potent
and reversible LA. One study reported it to be four to ﬁve
times more potent than Lignocaine [7]. It produced fewer2 International Journal of Dentistry
side eﬀects, better cardiovascular stability, and no sensitivity
r e a c t i o n s .I th a sb e e np r o v e nt ob ea se ﬀective as other LA
agents in ophthalmology [5, 6] and in subarachnoid blocks
[7]. It has not been thoroughly evaluated in the dental ﬁeld,
and therefore this study was done to evaluate its eﬃcacy.
The aim was to compare the eﬃcacy of 0.5% Centbucri-
dineHClto2%LignocaineHClwithAdrenaline(1:200000)
for various parameters required in the dental ﬁeld.
2.Objectives
(1) To assess and compare the onset (in seconds), dura-
tion (in minutes), and depth (using a visual analogue
sore) of anesthesia in healthy adults between Ligno-
caine and Centbucridine.
(2) To monitor and compare the cardiovascular response
(pulse and blood pressure) in patients on the two
LAs.
(3) To identify any side eﬀects/allergic reactions to Cent-
bucridine.
3.MaterialsMethod
This was a double blind randomized control trial com-
paring the eﬀects of 2% Lignocaine HCI with adrenaline
(1:200000) and 0.5% Centbucridine HCI. It was done
during June 2009 till December 2009 on outpatients attend-
ing the Gujarat University, Government Dental College in
India. All patients were healthy adults according to ASA-
I classiﬁcation and aged between 18 and 60 years old. All
patients who attended as outpatients for dental extractions
and met the criteria were asked to participate in the study.
A total of 198 patients were included in the study. All of
the patients attended for the extraction of lower molars.
They each randomly received a single anesthetic dose of
either 0.5% Centbucridine HCI or 2% Lignocaine HCI with
adrenaline. They were unaware of which type of LA they
received. Each patient was asked to select one of two brown
sealed envelopes which contained the two treatment options.
The operator administered a single cartridge of LA
agent using the Inferior Alveolar Nerve block standardized
technique as described in Handbook of Local Anesthesia [1].
The operator was handed the loaded syringe by a qualiﬁed
medical nurse and was unaware of the type of LA that he
was administering. The name of the anesthetic ampoule was
covered with a permanent marker which ensured that the
operator was blinded.
The study population was divided into two groups:
Group I (Centbucridine) and Group II (Lignocaine). Pa-
tients with acute oral infections were excluded. Intradermal
sensitivity tests were done prior to administration of the LA,
and any patient who tested positive was excluded from the
study.
The rationale for the study including its objectives was
explained to each participant. Informed and written consent
was obtained from all patients. Ethics for the study was
obtained from the University Ethical Committee.
The onset, duration, depth, and cardiovascular measure-
ments were carried out by a qualiﬁed medical nurse. The
time taken for the onset and duration of local anesthesia was
measured using a stopwatch.
4. Criteriafor Assessment
4.1. Onset of Anesthesia (Measured in Seconds). This was
measured both objectively and subjectively by the patient in
seconds. Anesthesia was conﬁrmed objectively by a pinprick
test using a 20 gauge sterile needle which was applied
over the attached gingival of the tooth to be extracted. It
was conﬁrmed subjectively when the patient ﬁrst described
symptoms of anesthesia for example—numbness or tingling
sensation over lower lip. A qualiﬁed medical nurse measured
the onset using a stopwatch.
4.2. Duration of Anesthesia (Measured in Minutes). This
was the time interval between the onset of anesthesia and
when the patient reported subjective feelings of normal
sensation.Thiswasconﬁrmedobjectivelybythepinpricktest
as described above. A qualiﬁed medical nurse measured the
onset using a stopwatch.
4.3. Depth of Anesthesia. This was judged subjectively by the
patient using a standardized visual analogue score (VAS).
The score ranged from “0” to “5” with “0” being “no pain”
and “5” being the most severeintense pain, whichthe patient
could not bear. Each patient was asked to score the “amount”
of pain he/she felt during the extraction of the tooth. A low
score(0)meantthatthepatientfeltnopainatall;amoderate
score (1 and 2) meant that the patient felt mild pain; a score
of (3 and 4) meant that the patient felt moderate pain; a
high score (5) meant that the patient felt excruciating and
unbearable pain.
4.4. To Monitor and Compare CVS Response Using Blood Pres-
sure and Heart Rate. The systolic and diastolic blood pres-
sure(BP)wasmeasuredinmmofmercury,andthepulserate
was measured using beats per minute. The measurements
were done preoperatively (base line), and then at 10, 20, 30,
and 60 minute intervals after the administration of the LA.
All patients were seated and in the resting position when the
measurements were recorded. The same sphygmomanome-
ter was used for all patients, and the nurse completed
the recordings using standard guidelines.
4.5. Side Eﬀects/Allergic Reaction. Any signs of an allergic
reaction including itching, redness, and localized swelling
were recorded.




was compared between the two groups. Changes in the heart
rate (pulse), systolic, and diastolic blood pressure at various
time intervals were analyzed against preoperative values inInternational Journal of Dentistry 3
Table 1: Age and gender distribution.
Group Mean age Male Female Total
I 38.1 45 (45%) 55 (55%) 100
II 37.2 49 (50%) 49 (50%) 98
Total 37.7 94 (47%) 104 (53%) 198
Table 2: Onset and duration of anesthesia.
Parameters Group I (Mean ± SD) Group II (Mean ± SD) Statistical analysis
Onset (seconds) 162.92 ± 64.4 176.03 ± 58.2 P = 0.121
Duration of anesthesia (minutes) 151.01 ± 44.4 111.07 ± 24.9 P = 0.00
∗
Table 3: Depth Of anesthesia using the VAS.
VAS score Group I Group II Statistical analysis
0 82 (82%) 81 (83%) P = 0.134
1 18 (18%) 17 (17%) P = 0.135
Total 100 98
Table 4: Comparison of mean heart rate at various time intervals
using Centbucridine and Lignocaine.
Heart rate Centbucridine Lignocaine
Base line 75.50 P value 76.61 P value
10min after LA 76.16 (±4.16) 0.00∗ 77.42 (±2.73) 0.00∗
20min after LA 75.52 (±4.26) 0.65 76.61 (±3.31) X
30min after LA 75.50 (±4.28) X 76.61 (±3.31) X
60min after LA 75.50 (±4.28) X 76.61 (±3.31) X
each group. All statistical results less than P<0.05 were
considered to be statistically signiﬁcant.
5. Results
There was a fairly equitable distribution of cases between
the two groups in terms of age, gender, and baseline blood
pressure and pulse readings. A total of 198 patients met
the criteria and were included in the study. Of these, 100
patients received Centbucridine (Group I) and 98 received
Lignocaine (Group II). There were slightly more females
(53%) than males, and the average age was 37.7 years (see
Table 1).
The average time for the onset (seconds) and duration
(minutes) of anesthesia is reported in Table 2. Patients who
received Centbucridine reported a signiﬁcantly longer dura-
tion of anesthesia compared to those who received Ligno-
caine.
Table 3 shows the depth of anesthesia as recorded by the
patient using the Visual Analogue Score (VAS). The range
wasfrom0(nopain)to5(severe,unbearablepain).Noscore
morethan1wasnoted.Nosigniﬁcantdiﬀerenceswerefound
between the two LAs.
The mean heart rate (beats per minute) at diﬀerent time
intervals is shown below (Table 4). Both LAs signiﬁcantly
increased the heart rate at the 10 minutes interval. At the
other later time intervals, there was no signiﬁcant increase
in the mean heart rate.
In both groups, there was a statistically signiﬁcant
increase in systolic BP at the 10 minute interval, after which
there were no signiﬁcant changes. In terms of the mean
diastolic BP, there were no statistically signiﬁcant diﬀerences
in the BP over the time period intervals.
No patients required additional doses of LA solutions.
6. Discussion
There were almost equal numbers of patients in both groups,
and the age and gender distribution was equally distributed.
There were no signiﬁcant diﬀerences between the groups
in terms of demographical characteristics, and hence the
groups could be compared to each other. The average time
requiredforonsetofanesthesiawasjustunderthreeminutes,
and Centbucridine was signiﬁcantly shorter. On average,
patients felt the anesthetic eﬀect of Centbucridine about 14
seconds quicker than that of Lignocaine which is clinically
not signiﬁcant. These results are within the reported range of
initiation of anesthesia as reported by others to be between
1a n d6m i n u t e s[ 2, 9]. This could be due to the inherent
vasoconstrictive eﬀect of Centbucridine as compared to
Lignocaine.
The mean duration of anesthesia was signiﬁcantly
higher for Centbucridine compared to Lignocaine. Patients
reported an average anesthesia of 2.5 hours (151 minutes)
for Centbucridine compared to under 2 hours (111 minutes)
for Lignocaine. A possible reason could be the fact that since
Centbucridine has a natural vasoconstrictive eﬀect, the LA
solution remained close to and around the nerve tissue for
a longer period of time. The solution was prevented from
being absorbed and dispersed, and this could have resulted
in the longer duration of anesthetic time that was obtained.
Both LAs showed similar results in terms of depth of
anesthesia. No patients reported a score of more than 1
(mild annoying pain), and all patients were suﬃciently
anesthetized to carry out the procedures. This was similar to
other studies [8].
There was mild and transient elevation of heart rate
in both the groups at the 10 minute interval. However, at
all subsequent evaluations, the heart rate had returned to
the preanesthesia value. In all of the cases, the tooth was
extracted and treatment was complete within 10 minutes.4 International Journal of Dentistry
Therefore, after the 10 minute interval, the patients were
much more relaxed, the fear had decreased, and their anxiety
had been reduced. It was therefore understandable that their
heart rate was high at the 10 minute mark but reduced
and returned to normal by the 20 minute interval and at
all subsequent evaluations. This has been also reported in
other studies [2] and considered normal. There was no
diﬀerence between the blood pressure parameters of both
the LAs. Mild elevation of this parameter during initial time
was attributed due to anxiety and fear as discussed above.
This has also been reported by other authors [1, 2, 9].
Lignocaine has an inherent vasodilating property, which in
turnrequiresadrenaline.Thishasbeenshowntoincreasethe
blood pressure and heart rate in some studies [1, 9] and is
contraindicated to some medically compromised patients. In
this study, although there were no medically compromised
patients, Lignocaine did not signiﬁcantly increase the blood
pressures and heart rate.
There were no adverse or allergic reactions to either of
the LAs in our sample population. Earlier episodes of an
allergy to Lignocaine have been reported but are very rare
[10–12]. Since the sample population in the study consisted
of about 200 patients, it is not surprising that there were
no patients who reported adverse reactions. Centbucridine
has showed an antihistaminic activity by blocking the H1
histamine receptors which makes it an ideal LA agent in
patients with known allergy to other conventional LAs [2, 5].
However, it must be noted that the sample population in the
study was relatively small and as a result.
7. Conclusion
It can be concluded that Centbucridine produced a signiﬁ-
cantly longer duration of anesthesia. It worked just as eﬀec-
tivelyasthe“goldstandard”Lignocaine,matchingitinterms
of time of onset, depth of anesthesia, and cardiovascular
eﬀects. It produced no side eﬀects or toxic reactions and
conﬁrmed its safety for use in this sample population. We
can recommend Centbucridine as a LA agent for dental pro-
cedureswhichmaylastupto2hours.Itisalsorecommended
that Centbucridine could be conﬁdently used in medi-
cally compromised patients where Lignocaine or adrenaline
is contraindicated.
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